Autonomix is a development-stage medical device company building a catheter-based system to detect and ablate peripheral nerves from within the vascular system. The company utilizes a "sense, treat, verify" approach, using a microchip-tipped catheter to identify weak electrical signals and deliver radiofrequency (RF) energy to target nerves in a single procedure. This technology aims to provide higher sensitivity than existing electrophysiology equipment by amplifying and digitizing neural signals at the source. Autonomix focuses its initial application on pain management for pancreatic cancer patients, proposing its transvascular method as a more precise and verifiable alternative to existing treatments. The business model relies on recurring revenue from single-use disposable sensing and ablation catheters sold to hospitals, alongside the placement of RF generators and software. While Autonomix has conducted early proof-of-concept studies with third-party hardware, its proprietary sensing catheter is in the prototype stage and has not yet been tested in humans. The company plans to initiate U.S. clinical trials in late 2026 and targets FDA clearance by 2028. Autonomix intends to expand this technology into a platform for treating other visceral cancers, hypertension, and chronic pain conditions.